Observational evidence suggests that a treat-to-target (T2T) approach might be beneficial in axial spondyloarthritis. However, data from a prospective randomised study showing the efficacy of a T2T strategy compared to routine care are currently lacking. Additionally, there is no consensus about what should be measured and its specific target. These were the take-home messages presented by Dr Pedro Machado (University College London Hospitals, United Kingdom) discussing the pros and cons of adopting a T2T strategy in the management of axial spondyloarthritis .
The availability of biologic therapies has improved the clinical outcomes of patients with axial spondyloarthritis, which has raised the question if there is a role for T2T. Dr Machado explained that the concept involves changing or escalating therapy according to a predefined target, under the assumption that this may lead to better outcome compared to routine care. T2T is not only well establish...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Filgotinib in RA Patients with Inadequate Response or Naïve to Methotrexate Next Article
Cohort Study Shows Improvement During 25 Years of RA Treatment »
Table of Contents: EULAR 2019
Osteoarthritis and Osteoporosis
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.